Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 11/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 11/20 | 0.34 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.34 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.34 |
| ▸ | FAP | Q12884 | 3/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22698603 | 0.94 | SIRT2 (0.35) | SIRT2SIRT1SIRT3SIRT5FAP | |
| SCHEMBL20831162 | 0.92 | SIRT2 (0.36) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL19683931 | 0.92 | SIRT2 (0.37) | SIRT2SIRT1SIRT3SIRT5FAP | |
| SCHEMBL28953170 | 0.92 | SIRT2 (0.38) | SIRT2SIRT1SIRT3SIRT5FAP | |
| SCHEMBL16847844 | 0.91 | OPRM1 (0.33) | SIRT2SIRT1SIRT3FAPOPRM1 | |
| SCHEMBL17801960 | 0.91 | ITGB1 (0.34) | SIRT2SIRT1SIRT3SIRT5FAP | |
| SCHEMBL17813693 | 0.90 | RAB9A (0.36) | SIRT2SIRT1SIRT3FAPOPRM1 | |
| SCHEMBL21695294 | 0.89 | HDAC3 (0.37) | SIRT2SIRT1FAPOPRM1OPRD1 | |
| SCHEMBL17650868 | 0.89 | HDAC3 (0.32) | SIRT2SIRT1FAPOPRM1OPRD1 | |
| SCHEMBL26559935 | 0.89 | OPRM1 (0.36) | SIRT2SIRT1SIRT3SIRT5OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330102-A1 | PROTAC ANTIBODY CONJUGATES AND METHODS OF USE | GENENTECH, INC. | 2023-10-19 | — | — | US | disclosed |
| US-11666581-B2 | PROTAC antibody conjugates and methods of use | GENENTECH, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230067037-A1 | CONJUGATED CHEMICAL INDUCERS OF DEGRADATION AND METHODS OF USE | GENENTECH, INC. (US) | 2023-03-02 | — | — | US | disclosed |
| US-10632210-B2 | Peptidomimetic compounds and antibody-drug conjugates thereof | GENENTECH, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190175612-A1 | PROTAC ANTIBODY CONJUGATES AND METHODS OF USE | GENENTECH, INC. | 2019-06-13 | — | — | US | disclosed |
| US-20190083643-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2019-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330102-A1 | PROTAC ANTIBODY CONJUGATES AND METHODS OF USE | PSMA3, PSMA6, PSMA2 | SIRT2 3592/4885SIRT1 3425/4885SIRT3 3676/4885 |
| US-20190175612-A1 | PROTAC ANTIBODY CONJUGATES AND METHODS OF USE | PSMA3, PSMA6, PSMA2 | SIRT2 3592/4885SIRT1 3425/4885SIRT3 3676/4885 |
| US-10632210-B2 | Peptidomimetic compounds and antibody-drug conjugates thereof | DNPEP, LNPEP, BCR | SIRT2 3885/4885SIRT1 3409/4885SIRT3 4270/4885 |
| US-20230067037-A1 | CONJUGATED CHEMICAL INDUCERS OF DEGRADATION AND METHODS OF USE | ADRM1, SSB, FCER2 | SIRT2 3357/4885SIRT1 2691/4885SIRT3 3443/4885 |
| US-20190083643-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | DNPEP, LNPEP, BCR | SIRT2 3885/4885SIRT1 3409/4885SIRT3 4270/4885 |
| US-11666581-B2 | PROTAC antibody conjugates and methods of use | PSMA3, PSMA6, PSMA2 | SIRT2 3592/4885SIRT1 3425/4885SIRT3 3676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.